Treatment patterns and resource utilization among elderly Medicare patients with HR+/HER2-metastatic breast cancer

被引：0
|
作者：
Goyal, R. K.
Carter, G. C.
Nagar, S. N.
Smyth, E. N.
Price, G. L.
Huang, Y-J
Bromund, J. L.
Li, L.
Schilder, J. M.
Davis, K. L.
Kaye, J. A.
机构：
[1] RTI Hlth Solut, Res Triangle Pk, NC USA
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
[3] RTI Hlth Solut, Waltham, MA USA
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-08-19
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Real-world study of patients with HR+/ HER2-metastatic breast cancer treated with palbociclib and fulvestrant
    Robert, Nicholas
    Chen, Connie
    Doan, Justin
    Venkatasetty, Divea
    Espirito, Janet L.
    Aguilar, Kathleen M.
    FUTURE ONCOLOGY, 2025, 21 (01) : 83 - 94
  • [42] Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR +, HER2-metastatic breast cancer patients in Japan
    Nozawa, K.
    Terada, M.
    Onishi, M.
    Ozaki, Y.
    Takano, T.
    Fakhouri, W.
    Novick, D.
    Haro, J. M.
    Faris, L. H.
    Kawaguchi, T.
    Tanizawa, Y.
    Tsurutani, Junji
    BREAST CANCER, 2023, 30 (04) : 657 - 665
  • [43] HEALTHCARE RESOURCE USE AND COSTS OF CARE IN HR+/HER2-METASTATIC BREAST CANCER: A RETROSPECTIVE US CLAIMS DATA STUDY
    Collin, S.
    Tse, J.
    Shaikh, N. F.
    Near, A.
    Hamilton, E.
    Brufsky, A.
    Gradishar, W.
    Mehta, S.
    Long, G. H.
    Toms, N.
    VALUE IN HEALTH, 2024, 27 (06) : S134 - S134
  • [44] Time on treatment of everolimus, fulvestrant, and capecitabine for the treatment of HR+/HER2-metastatic breast cancer: A retrospective claims study in the US
    Li, N.
    Hao, Y.
    Kageleiry, A.
    Peeples, M.
    Fang, A.
    Koo, V.
    Guerin, A.
    CANCER RESEARCH, 2016, 76
  • [45] Breast cancer specific survival (BCSS) in HR+/HER2-metastatic breast cancer (mBC) from 2010 to 2019
    Brufsky, A. M.
    Kwan, M.
    Sandin, R.
    Karanth, S.
    Cha-Silva, A.
    Makari, D.
    Stergiopoulos, S.
    Goyal, R.
    ANNALS OF ONCOLOGY, 2023, 34 : S351 - S352
  • [46] Health care resource utilization and costs of Medicare-enrolled patients with HR+/HER2-metastatic breast cancer treated with a CDK4/6i in the first-line setting
    Behan, Emma
    Veenstra, David L.
    Bansal, Aasthaa
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2025, 31 (01): : 6 - 14
  • [47] REAL-WORLD ANALYSIS OF MEDICAL COSTS AND HEALTHCARE RESOURCE UTILIZATION IN ELDERLY WOMEN WITH HR+/HER2-METASTATIC BREAST CANCER RECEIVING EVEROLIMUS-BASED THERAPY OR CHEMOTHERAPY
    Hao, Y.
    Li, N.
    Fang, A.
    Koo, V
    Peeples, M.
    Kageleiry, A.
    VALUE IN HEALTH, 2016, 19 (03) : A145 - A145
  • [48] Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2-Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy
    Hao, Yanni
    Li, Nanxin
    Fang, Anna P.
    Koo, Valerie
    Peeples, Miranda
    Kageleiry, Andrew
    Wu, Eric Q.
    Guerin, Annie
    ADVANCES IN THERAPY, 2016, 33 (06) : 983 - 997
  • [49] Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2-metastatic breast cancer in the United States
    Goyal, Ravi K.
    Cuyun Carter, Gebra
    Nagar, Saurabh P.
    Nash Smyth, Emily
    Price, Gregory L.
    Parikh, Rohan C.
    Huang, Yu-Jing
    Li, Li
    Davis, Keith L.
    Kaye, James A.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (04) : 699 - 710
  • [50] Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2-metastatic breast cancer
    Zagami, Paola
    Esposito, Angela
    Salimbeni, Beatrice Taurelli
    Giachetti, Pier Paolo Maria Berton
    Scafetta, Roberta
    Lambertini, Matteo
    Di Maio, Massimo
    Curigliano, Giuseppe
    Criscitiello, Carmen
    Cinieri, Saverio
    BREAST, 2025, 79
12345